Latest Conference Articles

ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, has demonstrated early signs of biological activity when given as a single agent or in combination with pembrolizumab in patients with advanced solid tumors.

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas

November 15th 2021, 3:00pm

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

Telotristat Ethyl Improves Symptoms and Patient Satisfaction in Carcinoid Syndrome

November 15th 2021, 2:00pm

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.

Surufatinib/Toripalimab Combo Elicits Encouraging Efficacy in Advanced Neuroendocrine Carcinoma

November 13th 2021, 11:00am

The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.

Eftilagimod Alpha/Paclitaxel Combo Shows Improved OS in Metastatic HR+ Breast Cancer Subsets

November 12th 2021, 9:14pm

The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.

PD-L1/4-1BB–Directed Bispecific Antibody ATG-101 Shows Preclinical Efficacy Without Hepatotoxicity

November 12th 2021, 9:00pm

ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.

Innate Cell Engager Demonstrates Evidence of Improved EGFR Inhibition in Tumor Cell Lines

November 12th 2021, 8:26pm

The innate cell engager AFM24 showed greater efficacy in eliciting antibody-dependent cellular phagocytosis of EGFR wild-type and KRAS-mutant tumor cells compared with cetuximab.

DuoBody®-CD3x5T4 Induces Efficient T-cell Activation, Tumor Cell Killing in HNSCC Cell Lines

November 12th 2021, 7:55pm

The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.

Surufatinib Induces Robust Responses in US Patients with Extrapancreatic and Pancreatic NETs

November 12th 2021, 5:00pm

Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.

PEN-221 Demonstrates Clinical Benefit in Gastrointestinal NETs

November 10th 2021, 4:00pm

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021, 9:08pm

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

November 8th 2021, 9:04pm

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

November 8th 2021, 8:37pm

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

KRAS G12C Inhibitors Enter the Spotlight in NSCLC

November 8th 2021, 8:26pm

PER® Chemotherapy Foundation Symposium (CFS)

The era of direct inhibitors to treat KRAS G12C-mutated non-small cell lung cancer has arrived in the clinic.

Targeted Therapies Make Major Strides in mCRC Management

November 7th 2021, 2:00pm

The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.

Examining New Approaches to Management of Immune-Related AEs in Lung Cancer

November 6th 2021, 8:32pm

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021, 8:28pm

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Timing of Immunotherapy Stoppage in Lung Cancer Varies Depending on Progression, AEs, and Cure

November 6th 2021, 8:03pm

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

November 6th 2021, 2:00pm

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021, 2:00pm